Skip to main content

Media & Announcements

Dowiedz się więcej

Polpharma Group at CPHI Milan 2026: Strengthening Partnerships Across the Global Pharmaceutical Value Chain

At CPHI Milan 2026, a Polpharma delegation led by CEO Sebastian Szymanek met partners on APIs, finished dosage forms, CDMO services and new technologies.
Group News
October 21, 2026
Polpharma Group team at CPHI Milan 2026
Dowiedz się więcej

Polpharma at EFNI 2026: Building Innovation, Resilience and Europe’s Future

At EFNI 2026 in Sopot, Polpharma shared its innovation experience and joined debates on resilient supply chains and Europe’s industrial future.
Group News
October 21, 2026
Panel discussion at the European Forum for New Ideas (EFNI) 2026
Dowiedz się więcej

Polpharma strengthens it's position in CEE - Biofarm, the leader of the Romanian market, joins the Group.

Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe.
Group News
July 27, 2026
Dowiedz się więcej

Polpharma Group’s R&D supports growth in key therapeutic areas.

Polpharma Group's research and development capabilities support growth across its key therapeutic areas and strengthen its product pipeline.
Group News
June 26, 2026
Polpharma Group team at CPHI Milan 2026

Polpharma Group at CPHI Milan 2026: Strengthening Partnerships Across the Global Pharmaceutical Value Chain

At CPHI Milan 2026, a Polpharma delegation led by CEO Sebastian Szymanek met partners on APIs, finished dosage forms, CDMO services and new technologies.
Group News
October 21, 2026
Panel discussion at the European Forum for New Ideas (EFNI) 2026

Polpharma at EFNI 2026: Building Innovation, Resilience and Europe’s Future

At EFNI 2026 in Sopot, Polpharma shared its innovation experience and joined debates on resilient supply chains and Europe’s industrial future.
Group News
October 21, 2026

Polpharma strengthens it's position in CEE - Biofarm, the leader of the Romanian market, joins the Group.

Polpharma Group has completed the acquisition of the Romanian pharmaceutical company Biofarm. The transaction is a clear step in the execution of the Group’s growth strategy and strengthens its position in Central and Eastern Europe.
Group News
July 27, 2026

Polpharma Group’s R&D supports growth in key therapeutic areas.

Polpharma Group's research and development capabilities support growth across its key therapeutic areas and strengthen its product pipeline.
Group News
June 26, 2026

26th International Scientific Conference on Expert Education Programs.

Polpharma joins the 26th International Scientific Conference on Expert Education Programs (EPE2026), supporting expert-led pharmaceutical education.
Group News
June 1, 2026

Polpharma opens an office in India, strengthening global collaboration and API supply chain resilience

Polpharma Group opens an office in India, deepening collaboration with key API suppliers and strengthening supply chain resilience, quality and ESG standards.
Group News
March 13, 2026

Polpharma SA launches a project under the STEP initiative

Polpharma launches an NCBR-funded STEP project to build a platform for manufacturing ready-to-use oligonucleotide RNA medicines, worth nearly PLN 80 million.
Science & Innovation
February 12, 2026

Polpharma Group Announces Leadership Transition – Sebastian Szymanek appointed as its new President

Polpharma Group appoints Sebastian Szymanek as CEO; Markus Sieger steps down after ten years at the helm and continues as a Supervisory Board member.
People
October 24, 2025

Polpharma Group's environmental responsibility

Polpharma Group targets 17% GHG emission reduction by 2025 and 5% production waste reduction through ISO 14001-compliant environmental management.
Group News
October 13, 2025

Polpharma's HP API facility is live!

Polpharma opens Poland's first state-of-the-art facility for highly potent active pharmaceutical ingredients, securing Europe's pharma supply chain.
Group News
October 9, 2024

Tackling the Dynamic Challenge of N-nitrosamines Control with High Performance Analytical Instrumentation

Polpharma API partnered with Waters on LC-MS equipment to meet regulatory standards for nitrosamine detection and control.
Group News
May 14, 2024

First CADIFA certification from ANVISA for Etodolac

Polpharma secured first CADIFA certification from ANVISA, ensuring GMP compliance. This milestone streamlines multiple drug product registrations in Brazil.
Group News
February 6, 2024

Ampoules visual inspection and leak detection line for sale

Polfa Warszawa invites tenders to buy a decommissioned ampoule visual inspection and leak detection line (Eisai, ZMR and Brevetti devices).
Tender Notices
December 1, 2023

Aseptic glass vials filling line for sale

Polfa Warszawa invites tenders to buy a decommissioned 2008 Bosch aseptic filling line for glass vials, including washer, tunnel and capper.
Tender Notices
November 21, 2023

KiloLab Laboratory: strategic milestone achieved!

Polpharma launches KiloLab Laboratory for kilogram-scale development under GMP, featuring isolators and reactors for high-potency API production.
Group News
October 11, 2023

Pre-filled syringes filling and packaging line for sale

Polfa Warszawa invites tenders to buy a decommissioned pre-filled syringes filling and packaging line (Groninger filler, labeller, CAM blister).
Tender Notices
September 6, 2023

Aseptic ophthalmics filling line including the solution preparation units for sale

Polfa Warszawa invites tenders to buy a decommissioned aseptic ophthalmic liquids filling line including its solution preparation units.
Tender Notices
September 1, 2023

Aseptic glass vials filling line for sale

Polfa Warszawa invites tenders to buy a decommissioned 2008 Bosch filling line for glass vials, listed as device number 100019.
Tender Notices
July 10, 2023

Ryvu Therapeutics and Polpharma sign two agreements in the area of RVU120 active substance (API) production for Phase II clinical trials

Polpharma API manufactures RVU120 for Ryvu Phase II trials treating leukaemia and myelodysplastic syndrome in EUR 1.7 million deals.
Group News
July 6, 2023

Polpharma received Golden CSR Leaf for the 9th time

Polpharma receives the POLITYKA Gold CSR Leaf for the ninth time, recognising its environmental, social and governance leadership in Poland.
Corporate Social Responsibility
June 16, 2023

Cryogenic infrastructure at API facility

Cryochemistry below −80°C enables precise synthesis with reduced impurities. Polpharma scales cryogenic processes from laboratory to production scale.
Group News
December 8, 2022

Students want to work with us!

Students place Polpharma second in the Exact Sciences category of Universum's Most Attractive Employers Poland 2022 survey, just behind winner Pfizer.
Careers
November 7, 2022

Polpharma’s strategic investment in HP API facility, the first of this kind in Poland

Polpharma's HP API facility offers GMP kilo-lab production to 1.5 kg with analytical labs, establishing Poland as pillar of European pharmaceutical industry.
Group News
September 5, 2022

The Leonardo Innovation Program won the Gold Stevie Awards® gold statuette in the 19th edition of the prestigious international competition International Business Awards®!

The Leonardo employee innovation programme wins Gold at the Stevie International Business Awards for creativity, engagement and innovative communication.
Group News
August 16, 2022

Polpharma partners with Pikralida biopharmaceutical start-up

Polpharma partners with start-up Pikralida to make the PKL-021 drug substance under GMP for preclinical work and a phase one epilepsy-prevention trial.
Group News
July 19, 2022

Polpharma’s Compliance Team awarded by the Compliance Institute

The Compliance Institute honours Polpharma's Compliance Team in its Compliance Awards, recognising achievements in compliance management and whistleblowing.
Corporate Social Responsibility
June 6, 2022

Polpharma received another CSR Golden Leaf

Polpharma wins POLITYKA's CSR Golden Leaf for the eighth time, with its ISO 26000-based practices verified by independent auditor Deloitte Polska.
Corporate Social Responsibility
June 6, 2022

September 2019 was the date when the transformation process started in the API Business Unit of Polpharma.

Polpharma API implements KPI scoreboards and SQDCP methodology for performance management and continuous operational improvement.
Group News
September 7, 2021

The Stevie® Awards: triple gold for Polpharma

EcoVisit wins triple Gold at the 2021 Stevie International Business Awards for combining business goals, ecology and relations; four forests planted so far.
Corporate Social Responsibility
August 18, 2021

Polpharma awarded with Golden and Diamond CSR Leaves

Polityka weekly awards Polpharma the special Diamond CSR Leaf and a Golden CSR Leaf, honouring ten years of leadership in responsible, sustainable business.
Corporate Social Responsibility
June 11, 2021

Polpharma ranked #1 in the Pharmaceuticals and Biotechnology category in the Forbes Poland’s Best Employers 2021 ranking!

Polpharma takes first place in the Pharmaceuticals and Biotechnology category of Forbes Poland's Best Employers 2021, based on an anonymous industry survey.
Careers
March 30, 2021

Polpharma has received the 2020 Ethical Company title

Polpharma receives the 2020 Ethical Company title, recognising its ethics and compliance programme plus COVID-19 aid such as ventilators and hospital meals.
Corporate Social Responsibility
March 24, 2021

Polpharma at the top in the category of the exact sciences in the study „Most Attractive Employer Poland” 2020

Polpharma tops the Natural Sciences category in Universum's Most Attractive Employer Poland 2020 study, voted by over 16,000 students from 71 universities.
Careers
March 4, 2021

Polpharma API completed step 1. Risk Evaluation according to EMA’s request concerning presence of nitrosamines in drug products.

Polpharma completed EMA risk assessment for nitrosamines in chemically synthesised APIs, identifying optimisation parameters for highest quality.
Group News
December 17, 2020

Polpharma API: sign up for free webinars!

Polpharma API experts host free webinars covering EMA and FDA nitrosamine requirements and the importance of particle size in active substances.
Science & Innovation
October 21, 2020

Polpharma in the top five of Polish National Champions

Polpharma places fifth in Polityka Insight's National Champions 2020 ranking, taking third place for innovation and fourth for human capital.
Group News
October 20, 2020

On the way to the factory of the future in the pharmaceutical sector

Polpharma Group and Microsoft agree to digitise pharma manufacturing with IoT, machine learning, big data analytics and robotic process automation.
Group News
May 30, 2019

The new Vice-President joins Polpharma

Simon Clark, a commercial executive with over 20 years in pharma, becomes Polpharma Group's Chief Commercial Officer to drive growth in Rx and CHC markets.
People
March 19, 2019

Jerzy Starak receives an award from GUMed

The Medical University of Gdańsk honours Jerzy Starak for building Polpharma into a leading CEE pharmaceutical company and a partner for Polish science.
People
December 19, 2018

Polpharma becomes an Advocate for the Standard of Ethics

UN Global Compact Network Poland names Polpharma an Advocate for the Standard of Ethics, honouring its work promoting ethical standards in Polish business.
Corporate Social Responsibility
October 22, 2018

Students chose Polpharma as an Ideal Employer!

Polpharma retains first place in the Natural Sciences category of the Universum Award 2018, overtaking Google, Microsoft, Nestlé and Bayer among students.
Careers
September 25, 2018

STEVIE®AWARD 2018 for Polpharma!

Polpharma receives a Stevie Award and a Bronze Stevie at the 2018 International Business Awards for reputation management and brand renovation of the year.
Group News
August 20, 2018

Latest news

Previous
Next

Press releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
People
Polpharma Group
June 12, 2025

Markus Sieger takes the helm as President ad interim at Medicines for Europe

Polpharma Group CEO Markus Sieger takes over as President ad interim of Medicines for Europe, prioritising medicine access and off-patent manufacturing.
Group News
Polpharma Group
June 4, 2025

Polpharma Group Supports Urgent EU Action to Safeguard Access to Medicines and Strengthen European Pharmaceutical Sovereignty

Polpharma Group joins European off-patent industry leaders urging the EU to speed up pharma reform, strengthen the Bolar exemption and secure medicine supply.
Group News
Polpharma Group
May 13, 2025

Polpharma Group Joins the Call to Action to Finalize Pharmaceutical Reform and Secure Early and Sustainable Healthcare for European Patients

Polpharma Group joins the call to finalise EU pharmaceutical reform, arguing shorter exclusivity and early generic entry will cut costs and secure supply.
Group News
ZF Polpharma
April 9, 2025

Polpharma turns 90 years old!

Polpharma marks its 90th anniversary, celebrating nine decades as a pillar of drug safety in Poland and a leader among pharmaceutical companies.
Science & Innovation
ZF Polpharma
February 12, 2025

Polpharma Receives Grants for Research Projects

Polpharma secures research grants to develop inhaled complex generics for COPD and asthma and an injectable polypeptide generic for type 2 diabetes.
Filter
Filters
Close
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.

Latest stories

View all stories
featured
Science
July 1, 2026

Understanding the Oligonucleotide Market: A Foundation for Next‑Generation API Capabilities

Oligonucleotides drive fastest-growing API segment with 50% of pipelines using oligo-based candidates. Polpharma provides Nusinersen capabilities.
written by
Witold Kozak
,
Antonina Fryś
,
Read the story
highlights
Read the story
Science
June 3, 2026

Digital Twin at Polpharma API: Turning Manufacturing Data into Predictable Value

Digital Twin shifts manufacturing from reactive to preventive strategies. Compare batches against golden batch benchmarks to identify deviations in real time.
written by
Karol Sągol
,
Read the story
Society
June 3, 2026

Broadening Access: How Generic APIs Are Shaping the Future of SMA Treatment

Spinal muscular atrophy affects 1 in 10,000 live births. Generic API suppliers expand global access to disease-modifying treatments for this genetic disorder.
written by
Antonina Fryś
,
Read the story
Science
March 23, 2026

Antibody-Drug Conjugates (ADCs): Revolutionizing Cancer Treatment

ADCs deliver cytotoxic agents directly to cancer cells using monoclonal antibodies. The global market is projected to reach 27.8 billion USD by 2032.
Previous
Next

For the media

Media Kit

Logos, photography and the Group boilerplate.
ZIP file (112.28 kb) updated quarterly
Download
Next

Group factsheet

Revenue, footprint, pipeline, employment and history.
Pdf file (112.28 kb) updated quarterly
Download
Next

Press Contact

Logos, photography and the Group boilerplate.
press@polpharma.com
RESPONDS WITHIN ONE BUSINESS DAY
rzecznik@polpharma.com
Next